New drug trial aims to turn immune system against tough brain tumors
NCT ID NCT05916313
Summary
This study is testing a new drug called BI 764532 for adults with an aggressive type of brain cancer (glioma) that has stopped responding to standard treatments. The drug works by linking the patient's own immune cells to the cancer cells to help the body fight the tumor. The main goal is to find the highest dose that is safe and tolerable for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cantonal Hospital of Aarau
Aarau, CH-5001, Switzerland
-
Erasmus Medisch Centrum-ROTTERDAM-50697
Rotterdam, 3015 GD, Netherlands
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Klinikum der Universität München AÖR
München, 81377, Germany
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Salzburg Cancer Research Institute
Salzburg, 5020, Austria
-
University Hosp. Zurich
Zurich, 8901, Switzerland
-
University Hospital of Lausanne
Lausanne, 1101, Switzerland
-
University of California Irvine
Orange, California, 92868, United States
-
Universitätsklinikum Frankfurt
Frankfurt, 60596, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
Conditions
Explore the condition pages connected to this study.